258 related articles for article (PubMed ID: 19075676)
1. CD44 and EpCAM: cancer-initiating cell markers.
Marhaba R; Klingbeil P; Nuebel T; Nazarenko I; Buechler MW; Zoeller M
Curr Mol Med; 2008 Dec; 8(8):784-804. PubMed ID: 19075676
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer-initiating cell exosome message transfer into noncancer-initiating cells: the importance of CD44v6 in reprogramming.
Wang Z; Sun H; Provaznik J; Hackert T; Zöller M
J Exp Clin Cancer Res; 2019 Mar; 38(1):132. PubMed ID: 30890157
[TBL] [Abstract][Full Text] [Related]
3. Exosomes, metastases, and the miracle of cancer stem cell markers.
Wang Z; Zöller M
Cancer Metastasis Rev; 2019 Jun; 38(1-2):259-295. PubMed ID: 31030373
[TBL] [Abstract][Full Text] [Related]
4. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy.
Mitra M; Kandalam M; Harilal A; Verma RS; Krishnan UM; Swaminathan S; Krishnakumar S
Mol Vis; 2012; 18():290-308. PubMed ID: 22328825
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment.
Wei HJ; Yin T; Zhu Z; Shi PF; Tian Y; Wang CY
Hepatobiliary Pancreat Dis Int; 2011 Aug; 10(4):428-34. PubMed ID: 21813394
[TBL] [Abstract][Full Text] [Related]
6. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Zöller M
Nat Rev Cancer; 2011 Apr; 11(4):254-67. PubMed ID: 21390059
[TBL] [Abstract][Full Text] [Related]
7. CD44v6-competent tumor exosomes promote motility, invasion and cancer-initiating cell marker expression in pancreatic and colorectal cancer cells.
Wang Z; von Au A; Schnölzer M; Hackert T; Zöller M
Oncotarget; 2016 Aug; 7(34):55409-55436. PubMed ID: 27419629
[TBL] [Abstract][Full Text] [Related]
8. Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research.
Han ME; Jeon TY; Hwang SH; Lee YS; Kim HJ; Shim HE; Yoon S; Baek SY; Kim BS; Kang CD; Oh SO
Cell Mol Life Sci; 2011 Nov; 68(21):3589-605. PubMed ID: 21448722
[TBL] [Abstract][Full Text] [Related]
9. Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties.
Wang M; Xiao J; Shen M; Yahong Y; Tian R; Zhu F; Jiang J; Du Z; Hu J; Liu W; Qin R
Int J Cancer; 2011 Jan; 128(1):72-81. PubMed ID: 20232394
[TBL] [Abstract][Full Text] [Related]
10. Pivotal role of CD38 biomarker in combination with CD24, EpCAM, and ALDH for identification of H460 derived lung cancer stem cells.
Karimi-Busheri F; Zadorozhny V; Li T; Lin H; Shawler DL; Fakhrai H
J Stem Cells; 2011; 6(1):9-20. PubMed ID: 22997842
[TBL] [Abstract][Full Text] [Related]
11. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.
Palagani V; El Khatib M; Kossatz U; Bozko P; Müller MR; Manns MP; Krech T; Malek NP; Plentz RR
PLoS One; 2012; 7(10):e46514. PubMed ID: 23094026
[TBL] [Abstract][Full Text] [Related]
12. CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression.
Wang Z; Zhao K; Hackert T; Zöller M
Front Cell Dev Biol; 2018; 6():97. PubMed ID: 30211160
[TBL] [Abstract][Full Text] [Related]
13. Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.
Tauro BJ; Greening DW; Mathias RA; Mathivanan S; Ji H; Simpson RJ
Mol Cell Proteomics; 2013 Mar; 12(3):587-98. PubMed ID: 23230278
[TBL] [Abstract][Full Text] [Related]
14. Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis.
Bertolini G; D'Amico L; Moro M; Landoni E; Perego P; Miceli R; Gatti L; Andriani F; Wong D; Caserini R; Tortoreto M; Milione M; Ferracini R; Mariani L; Pastorino U; Roato I; Sozzi G; Roz L
Cancer Res; 2015 Sep; 75(17):3636-49. PubMed ID: 26141860
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer stem cell markers and exosomes - the incentive push.
Heiler S; Wang Z; Zöller M
World J Gastroenterol; 2016 Jul; 22(26):5971-6007. PubMed ID: 27468191
[TBL] [Abstract][Full Text] [Related]
16. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.
Terris B; Cavard C; Perret C
J Hepatol; 2010 Feb; 52(2):280-1. PubMed ID: 20006402
[TBL] [Abstract][Full Text] [Related]
17. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics.
Wei X; Dombkowski D; Meirelles K; Pieretti-Vanmarcke R; Szotek PP; Chang HL; Preffer FI; Mueller PR; Teixeira J; MacLaughlin DT; Donahoe PK
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18874-9. PubMed ID: 20952655
[TBL] [Abstract][Full Text] [Related]
18. CD44: More than a mere stem cell marker.
Morath I; Hartmann TN; Orian-Rousseau V
Int J Biochem Cell Biol; 2016 Dec; 81(Pt A):166-173. PubMed ID: 27640754
[TBL] [Abstract][Full Text] [Related]
19. Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites.
Wintzell M; Hjerpe E; Åvall Lundqvist E; Shoshan M
BMC Cancer; 2012 Aug; 12():359. PubMed ID: 22901285
[TBL] [Abstract][Full Text] [Related]
20. Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater.
Piscuoglio S; Lehmann FS; Zlobec I; Tornillo L; Dietmaier W; Hartmann A; Wünsch PH; Sessa F; Rümmele P; Baumhoer D; Terracciano LM
J Clin Pathol; 2012 Feb; 65(2):140-5. PubMed ID: 22130902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
